SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
194.55 EUR
+5.05 (+2.66%)
We assign a fundamental rating of 5 out of 10 to 56S1. 56S1 was compared to 19 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
Each year in the past 5 years 56S1 has been profitable.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1 has a Return On Assets of 3.35%. This is comparable to the rest of the industry: 56S1 outperforms 42.11% of its industry peers.
Looking at the Return On Equity, with a value of 6.54%, 56S1 is in line with its industry, outperforming 42.11% of the companies in the same industry.
With a Return On Invested Capital value of 5.94%, 56S1 perfoms like the industry average, outperforming 52.63% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for 56S1 is above the industry average of 7.47%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
With a decent Profit Margin value of 8.96%, 56S1 is doing good in the industry, outperforming 63.16% of the companies in the same industry.
56S1's Profit Margin has declined in the last couple of years.
56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 68.42% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
The Gross Margin of 56S1 (45.64%) is better than 73.68% of its industry peers.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
56S1 has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, 56S1 has more shares outstanding
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
56S1 has an Altman-Z score of 4.26. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.26, 56S1 belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio of 6.84. This is comparable to the rest of the industry: 56S1 outperforms 47.37% of its industry peers.
56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 57.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.26 |
ROIC/WACC0.68
WACC8.79%
2.3 Liquidity
A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
56S1 has a worse Current ratio (1.05) than 63.16% of its industry peers.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1's Quick ratio of 0.50 is on the low side compared to the rest of the industry. 56S1 is outperformed by 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
56S1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.11%, which is quite impressive.
Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 4.19% on average per year.
The Revenue has been growing slightly by 7.72% in the past year.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
The Earnings Per Share is expected to grow by 22.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.12% on average over the next years. This is quite good.
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 45.14, 56S1 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 73.68% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (25.65), we can say 56S1 is valued expensively.
A Price/Forward Earnings ratio of 36.54 indicates a quite expensive valuation of 56S1.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 73.68% of the companies are valued more cheaply.
56S1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 34.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.14 | ||
| Fwd PE | 36.54 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 78.95% of the companies listed in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 50.56 | ||
| EV/EBITDA | 26.24 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of 56S1 may justify a higher PE ratio.
56S1's earnings are expected to grow with 22.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.6
PEG (5Y)10.76
EPS Next 2Y23.34%
EPS Next 3Y22.86%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.37%, which is pretty low.
56S1's Dividend Yield is comparable with the industry average which is at 0.73.
With a Dividend Yield of 0.37, 56S1 pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.41% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.41%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
FRA:56S1 (11/24/2025, 7:00:00 PM)
194.55
+5.05 (+2.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.94B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target238.84 (22.77%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.26%
PT rev (3m)-0.06%
EPS NQ rev (1m)7.13%
EPS NQ rev (3m)9.76%
EPS NY rev (1m)0.52%
EPS NY rev (3m)0.52%
Revenue NQ rev (1m)0.74%
Revenue NQ rev (3m)5.19%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.14 | ||
| Fwd PE | 36.54 | ||
| P/S | 6.43 | ||
| P/FCF | 50.56 | ||
| P/OCF | 25.92 | ||
| P/B | 4.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.24 |
EPS(TTM)4.31
EY2.22%
EPS(NY)5.32
Fwd EY2.74%
FCF(TTM)3.85
FCFY1.98%
OCF(TTM)7.51
OCFY3.86%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.6
PEG (5Y)10.76
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.26 |
F-Score8
WACC8.79%
ROIC/WACC0.68
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.68%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 6 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.41%.